4J Therapeutics, Inc.

4J Therapeutics, Inc. is a preclinical biopharmaceutical company focused on the development of novel, broad-spectrum antiviral agents for the treatment of influenza and other serious viral infections using a unique programmable antiviral platform approach. Our strategy employs the rapid identification of essential RNA motifs encoded in the genome of viruses of public health concern, and targeting them with a new class of potent, programmable, and globally deployable antiviral therapeutics. Our preclinical pipeline consists of new chemical entities targeting influenza A virus and other viruses of major medical importance and pandemic potential.